Marizomib CAS 437742-34-2

Product Description:

Product Name: Marizomib CAS NO: 437742-34-2

Synonyms:

(-)-SalinosporaMide A;

SalinosporaMide A;

Marizomib (Salinosporamide A);

Chemical & Physical Properties:

Appearance: White to beige powder

Assay :≥99.0%

Density: 1.348±0.06 g/cm3(Predicted)

Melting Point: 168-170 ℃

Boiling Point: 547.0±50.0 ℃(Predicted)

Storage temp.: -20℃

Pka: 13.10±0.20(Predicted)

Safety Information:

RTECS: RN6803500

Salinosporamide A is a potent proteasome inhibitor being studied as a potential anticancer agent. It entered phase I human clinical trials for the treatment of multiple myeloma, only three years after its discovery in 2003. This marine natural product is produced by the obligate marine bacteria Salinispora tropica and Salinispora arenicola, which are found in ocean sediment. Salinosporamide A belongs to a family of compounds, known collectively as salinosporamides, which possess a densely functionalized γ-lactam-β-lactone bicyclic core. Marizomib (Salinosporamide A) is second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.